Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

True Health IP LLC

Sagres Discovery, Inc.

Michael Rowe

Edward Moler

Michael P McKenna

Robert W Gerwien

Carla C Heise

Robert Booher

Albert Lai

Keith Stewart

Christin Tse

Edward J Moler, Jr

Esther Masih-Khan

Suzanne Trudel

Abdallah Fanidi

Xie Xu

Guoying Yu

A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.

Method for determining risk of diabetes

Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.

Effects of inhibitors of FGFR3 on gene transcription

This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.

SEMA4D in cancer diagnosis, detection and treatment

Growing community of inventors

Oakland, CA, United States of America

Michael Rowe